JCM | Free Full-Text | Safety, Feasibility and Technical Considerations from a Prospective, Observational Study—CIREL: Irinotecan-TACE for CRLM in 152 Patients
All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide | JCO Oncology Practice
Dose Escalation and DLT of Increased Irinotecan Doses in Patients... | Download Table
DBL Irinotecan Full Prescribing Information, Dosage & Side Effects | MIMS Malaysia
Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours | British Journal of Cancer
Irinotecan Hydrochloride Injection, SDV | Eugia US
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study | British Journal of Cancer
Irinotecan Hydrochloride, USP - Xiromed
359 Erhöhte Irinotecan-Toxizität bei reduzierter UGT1A1-Aktivität - IMD Institut für medizinische Diagnostik, Labor
Irinotecan dose escalation according to the UGT1A1 genotype | Download Table
Irinotecan hydrochloride Injection USP 100mg/5ml - Taj Generics Pharmaceuticals | Taj Pharma
Irinotecan Pathway, Pharmacokinetics
Cost–effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer | Pharmacogenomics